Daraxonrasib's 13.2-Month Signal in Pancreatic Cancer

On April 13, 2026, Revolution Medicines disclosed topline results from RASolute 302, a global Phase 3 trial of its oral RAS inhibitor daraxonrasib in previously treated metastatic pancreatic cancer. The headline figure is a median overall survival of 13.2 months on daraxonrasib compared with 6.7 months on investigator's-choice chemotherapy, with a hazard ratio of 0.40 and a p-value below 0.0001, according to trial coverage from CancerNetwork. One trial. One oral pill. One disease where, for decades, survival needles have barely moved.

That last point is what makes the readout worth reading carefully. Pancreatic ductal adenocarcinoma (PDAC) is, per the Pancreatic Cancer Action Network, the sole major cancer whose five-year survival sits below 20 percent; PanCAN puts the figure at 13 percent. A second-line therapy that roughly doubles median survival in a disease with that baseline is not an incremental win. It is the kind of result the field has been told, repeatedly, is not currently achievable with any small molecule — because the target in question, RAS, was until recently considered undruggable.

Why RAS Has Been the Hardest Target in Oncology

For decades, RAS proteins were the textbook example of an oncology target that refused to cooperate. The proteins are small, smooth-surfaced GTPases with no obvious deep hydrophobic pocket for a drug to latch into. Mutant RAS sits at the top of proliferation pathways in a large fraction of human cancers, and the inability to drug it cleanly shaped two generations of pharmacology workarounds — MEK inhibitors, farnesyltransferase programs, synthetic-lethality screens — that produced many failures and very few approvals.

The first direct RAS inhibitors, sotorasib and adagrasib, changed the picture in non-small-cell lung cancer by exploiting a reactive cysteine residue unique to the KRAS G12C mutation. Those drugs bind the inactive, GDP-loaded form of RAS — what the field calls the RAS-OFF state. That approach is elegant but narrow: only one specific G12 mutation carries the cysteine those drugs need, and in pancreatic cancer, G12C is a minor subset of RAS mutations. The dominant PDAC mutations are G12D, G12V, and G12R, none of which are approachable with the same covalent chemistry.

Daraxonrasib, known during development as RMC-6236, is built on a different premise. Inside Precision Medicine characterizes it as an "oral RAS(ON) multi-selective, non-covalent inhibitor" that targets the active, GTP-bound state of RAS. Mechanistically the drug recruits cyclophilin A, a chaperone already present in every cell, and the resulting drug-chaperone complex sits at the interface between active RAS and its downstream effectors. Rather than reaching into a pocket that does not exist, the molecule builds a composite binding surface using a protein the cell already makes — and by targeting the conformation rather than a specific cysteine, it can in principle engage multiple RAS variants and wild-type RAS with the same chemistry.

That "multi-selective" label is load-bearing. Inside Precision Medicine's account of the trial says the enrolled population included tumors harboring G12 variants (G12D, G12V, G12R), as well as G13 and Q61 mutations, and extended to patients without identified RAS mutations. Previous direct-RAS programs could not realistically address that full mutational spread with a single molecule. The pharmacology is the clinical thesis.

What RASolute 302 Actually Tested

The trial design described by CancerNetwork is deliberately pragmatic. Roughly 501 adults with histologically or cytologically confirmed metastatic PDAC and an ECOG performance status of 0 or 1 were randomized one-to-one between daraxonrasib at 300 mg orally once daily and investigator's-choice standard cytotoxic chemotherapy. All patients had already failed a prior line of therapy, which means the comparator was, in practice, the kind of second-line chemotherapy regimens — FOLFIRINOX or gemcitabine/nab-paclitaxel variants — that clinicians actually reach for in the clinic.

That framing matters because second-line pancreatic trials are a graveyard of null results. Patients at this point are sicker, are carrying more cumulative toxicity from prior treatment, and are statistically unlikely to tolerate or benefit from additional cytotoxic therapy. The historical comparator survival of 6.7 months reported in RASolute 302 is consistent with published second-line PDAC trials; it is not an artificially weak control arm. The test daraxonrasib had to pass was not "beat a sugar pill," but "beat the best chemotherapy a modern oncologist would actually prescribe."

The topline verdict from Revolution Medicines is that the drug cleared that bar on both primary endpoints: progression-free survival and overall survival. The median-OS doubling is the number most coverage has led with; the hazard ratio of 0.40, as characterized by CancerNetwork, translates to a substantial reduction in the risk of death over the study's follow-up window. P-values below 0.0001 in a 500-patient second-line pancreatic trial are not subtle.

The Safety Question

Oral targeted therapies can deliver survival benefits and still fail the clinical tolerability test. Rash, diarrhea, and mucosal toxicity are familiar issues across RAS-pathway drugs, and a drug patients cannot stay on is a drug whose survival curves eventually flatten.

CancerNetwork's coverage of the Phase 3 readout characterized the safety signal qualitatively: daraxonrasib was "generally well tolerated, with no new safety signals and a manageable safety profile." That language is corporate and aggregated — it is not the same as a published adverse-event table — but "no new safety signals" at Phase 3 scale is a meaningful qualitative claim, even if the full adverse-event tabulation will only be scrutinizable once the ASCO 2026 presentation and downstream peer-reviewed publication land.

A separate dimension worth naming: this is an oral, once-daily pill versus intravenous cytotoxic chemotherapy. Even if the two arms had matched on survival, the treatment experience differs. STAT News reported on a single enrolled patient — former U.S. Senator Ben Sasse, diagnosed with metastatic pancreatic cancer in December 2025 and given an initial prognosis of three to four months — whose CA 19-9 tumor marker fell from above 8,000 to 374, with approximately 60 percent tumor-volume reduction on treatment. One patient's experience is not a data point; it is an illustration. But it captures the dimension that survival curves compress: quality-of-life differential in a disease where the conventional second-line chemo can be as debilitating as the disease itself.

How Big a Step Is "Unprecedented"

The word "unprecedented" appears across the press coverage, and it is worth interrogating rather than accepting. Revolution Medicines' own phrasing, relayed through CancerNetwork, is that no prior drug has shown an overall survival benefit greater than a year in a Phase 3 pancreatic cancer trial. Without the full published dataset, the clean comparison to defend is the one already in the public record: 13.2 months on drug versus 6.7 months on chemotherapy, on a pre-specified primary endpoint, in a roughly 500-patient global trial.

Principal investigator Brian M. Wolpin of Dana-Farber, quoted in CancerNetwork, called it "a very important advance for the field that I expect will be practice changing." CEO Mark A. Goldsmith, in the same outlet, framed the readout as "potentially transformative." PanCAN Chief Scientific and Medical Officer Dr. Anna Berkenblit characterized it in terms patients can read directly: "Patients who took daraxonrasib lived a median of 13.2 months, compared to 6.7 months for patients who received chemotherapy." Three different framings, one shared observation.

The broader field context hardens the claim. PanCAN explicitly describes daraxonrasib as the first RAS inhibitor to extend survival in previously treated metastatic pancreatic adenocarcinoma. Inside Precision Medicine describes PDAC as "the most RAS-addicted of all major cancers." A positive Phase 3 of a multi-selective RAS(ON) inhibitor in this disease is therefore not a proof-of-concept signal for one mutation in one lineage; it is a proof-of-platform signal for a class that could plausibly touch large fractions of several cancer types.

What This Does Not Tell Us — Yet

A careful reading should not slide from "practice-changing second-line survival signal" to "cancer solved." Several specific unknowns remain unresolved in the current disclosure.

1. Subgroup performance. The enrolled population mixed G12D, G12V, G12R, G13, Q61, and RAS wild-type tumors. The topline numbers describe the intent-to-treat result. Whether the survival benefit is uniform across mutation types — or is concentrated in the most common G12 variants — is not resolvable from the press-release-level disclosure. Full subgroup analyses are expected at the 2026 ASCO Annual Meeting per Revolution Medicines.

2. Duration of response and resistance. Median OS of 13.2 months is extraordinary for this disease but finite. PanCAN's statement flags that resistance development is a live concern and that combination strategies will likely be necessary for more durable benefit. RAS-pathway rewiring, MAPK reactivation, and clonal emergence of non-RAS-driver mutations are all plausible escape routes that have been documented for the earlier RAS-OFF inhibitor class.

3. First-line generalizability. RASolute 302 was conducted in previously treated patients. A separate Phase 3, RASolute 303, is being launched in first-line metastatic PDAC, often combined with chemotherapy, per Revolution Medicines' disclosures. Until that trial reads out, the first-line survival contribution of daraxonrasib is an expectation, not a finding.

4. Comparator-arm interpretation. "Investigator's-choice chemotherapy" is a pragmatic design that captures real-world practice, but it means the 6.7-month control is a composite of several regimens in varying proportions rather than a single standardized comparator. Cross-trial comparisons to any specific prior second-line pancreatic study should therefore be qualitative rather than numerical.

5. Peer review. This is a topline press release followed by trade-press coverage, not a peer-reviewed publication. The hazard ratio, p-value, safety tabulation, and subgroup splits all need to clear independent review at ASCO and in a downstream journal before the field can fully calibrate confidence.

The Development and Regulatory Path

The structural context around the readout matters as much as the numbers. Daraxonrasib carries prior FDA breakthrough therapy designation for previously-treated PDAC with KRAS G12 mutations, along with an orphan drug designation, per CancerNetwork. Revolution Medicines has signaled an intent to submit a New Drug Application under the Commissioner's National Priority Voucher pathway, with full Phase 3 data slated for ASCO 2026 presentation, according to the company's own press communication.

That combination of designations and vouchers does not guarantee approval, but it does strongly suggest that FDA will work this file on an accelerated timeline, and that the agency already views the asset as high-priority. Second-line metastatic PDAC is an indication where the regulatory calculus leans toward letting a meaningful survival benefit reach patients quickly — the disease moves faster than the typical review cycle.

Implications for the Next Two Years

For oncologists, the near-term question is practical: when daraxonrasib reaches the label, it will reset the default second-line conversation for RAS-mutant metastatic PDAC away from cytotoxic chemotherapy and toward a once-daily oral pill with a manageable safety profile. Current multidisciplinary tumor-board templates for PDAC will need updating, and molecular-testing workflows that previously triaged G12C as the only actionable RAS variant will need to expand to capture the broader G12/G13/Q61 spectrum.

For drug developers, the Phase 3 result is a platform validation for the RAS(ON) tri-complex approach. If multi-selective RAS(ON) inhibition produces a survival signal of this magnitude in the most RAS-addicted tumor type, investment cases for related assets — other RAS(ON) chemotypes, mutation-specific RAS(ON) inhibitors, and RAS-combination regimens — become materially stronger. Expect an acceleration of combination trials pairing daraxonrasib with chemotherapy, immunotherapy, and other pathway-inhibitor backbones.

For patients and advocacy groups, the practical takeaway is that the pipeline of RAS-targeting therapies is no longer theoretical. PanCAN's statement explicitly frames the result as "a real opportunity to bring new hope," tempered by the acknowledgment that resistance and combination-therapy research must continue.

For investors and health-system planners, the readout reframes the commercial opportunity in PDAC. An oral, once-daily therapy that addresses more than 90 percent of a tumor type — the share of PDAC tumors carrying RAS mutations, per PanCAN — and delivers a second-line survival doubling is a different commercial and reimbursement profile than the narrow, mutation-specific approvals that have dominated precision oncology so far.

The Harder Picture

None of this makes pancreatic cancer a solved problem. A second-line median OS of 13.2 months is transformative in the context of 6.7, but the absolute number is still measured in single-digit increments beyond a year. Five-year survival in PDAC will not jump to modern lung-cancer levels on the basis of one Phase 3, and the durability of benefit is the next frontier. The open question — and it is an interesting one — is whether the RAS(ON) class ultimately functions as a standalone oral pill that keeps working, or as the backbone of combination regimens that hold resistance at bay long enough to convert a modal response into a long tail of survivors.

Either answer is a field-changing one. For a disease that has resisted nearly every targeted approach thrown at it for four decades, having the field-changing question be "which kind of win is this" rather than "will it work at all" is itself the news.

Key Takeaways

• Daraxonrasib, an oral RAS(ON) multi-selective inhibitor from Revolution Medicines, produced median overall survival of 13.2 months versus 6.7 months on chemotherapy in the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer, per CancerNetwork.
• The drug's tri-complex mechanism targets active, GTP-bound RAS and engages multiple mutant variants plus wild-type RAS — a materially wider spectrum than earlier RAS-OFF covalent inhibitors limited to G12C, as characterized by Inside Precision Medicine.
• Pancreatic cancer carries a five-year survival rate of only 13 percent and RAS mutations in over 90 percent of tumors, per PanCAN, making a positive RAS(ON) readout disproportionately consequential for the field.
• Open questions include mutation-subgroup performance, resistance and combination strategy, first-line data from the forthcoming RASolute 303 trial, and formal peer review of the full dataset at ASCO 2026.
• A Commissioner's National Priority Voucher NDA and prior FDA breakthrough and orphan designations position the asset for an accelerated U.S. regulatory path, per Revolution Medicines.